Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | BACE1 | P56817 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | CCR2 | P41597 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | ESR1 | P03372 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5428090 | 0.84 | DRD4 (0.63) | DRD4LMNAALDH1A1POLBSIGMAR1 | |
| SCHEMBL25860058 | 0.84 | ALDH1A1 (0.65) | LMNAALDH1A1POLBGAA | |
| SCHEMBL2234131 | 0.84 | LMNA (0.46) | LMNAALDH1A1POLBSIGMAR1HRH3 | |
| SCHEMBL10245285 | 0.82 | MAPT (0.53) | GAAKDM4EMAPT | |
| SCHEMBL21287946 | 0.82 | LMNA (0.47) | LMNAALDH1A1POLBSIGMAR1HRH3 | |
| SCHEMBL20314570 | 0.82 | KCNH2 (0.51) | DRD4LMNAALDH1A1POLBSIGMAR1 | |
| SCHEMBL855234 | 0.81 | SIGMAR1 (0.69) | DRD4LMNAALDH1A1POLBSIGMAR1 | |
| SCHEMBL3663957 | 0.81 | LPL (0.43) | LMNAALDH1A1POLBSIGMAR1HRH3 | |
| Water SCHEMBL27829325 | 0.81 | SIGMAR1 (0.43) | LMNAALDH1A1POLBSIGMAR1HRH3 | |
| Hydrochloric Acid SCHEMBL4074661 | 0.80 | SIGMAR1 (0.67) | DRD4LMNAALDH1A1POLBSIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219894-A1 | DISUBSTITUTED ADAMANTYL DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION FOR SUPPRESSING CANCER GROWTH COMPRISING SAME AS ACTIVE INGREDIENT | ONECUREGEN CO., LTD. (KR) | 2023-07-13 | — | — | US | disclosed |
| EP-1910334-A2 | COMPOUNDS AND METHODS FOR TREATMENT OF AMYLOID-BETA-PEPTIDE RELATED DISORDERS | Exonhit Therapeutics SA (FR) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007034329-A2 | COMPOUNDS AND METHODS FOR TREATMENT OF AMYLOID-BETA-PEPTIDE RELATED DISORDERS | EXONHIT THERAPEUTICS SA (FR) | 2007-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219894-A1 | DISUBSTITUTED ADAMANTYL DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION FOR SUPPRESSING CANCER GROWTH COMPRISING SAME AS ACTIVE INGREDIENT | AK2, CS, GOT2 | DRD4 4258/4885LMNA 3870/4885ALDH1A1 509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.